Clinical Trial Update: Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update describes evaluating subcutaneous blinatumomab for safety and efficacy in patients with measurable residual disease-positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (Blincyto) (blinatumomab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 2 Study, Blinatumomab | Phase 2 | Status: NOT_YET_RECRUITING